{
    "body": "Which disease is treated with lucinactant?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15813666", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18822258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22791092", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16896079", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23473590", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16452346", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23032799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23118645", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22821059", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22859930", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17533176", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15805381", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15805380"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1609686", 
            "o": "lucinactant"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1609686", 
            "o": "http://linkedlifedata.com/resource/umls/label/A20633234"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A20633234", 
            "o": "lucinactant"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1609686", 
            "o": "http://linkedlifedata.com/resource/umls/label/A8604556"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A8604556", 
            "o": "lucinactant"
        }
    ], 
    "ideal_answer": [
        "Lucinactant us used for the prevention of respiratory distress syndrome in premature infants."
    ], 
    "exact_answer": [
        "respiratory distress syndrome"
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4002240", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194", 
        "http://www.disease-ontology.org/api/metadata/DOID:4"
    ], 
    "type": "factoid", 
    "id": "5896271178275d0c4a000004", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 85, 
            "text": "Lucinactant for the prevention of respiratory distress syndrome in premature infants.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473590", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 174, 
            "offsetInEndSection": 795, 
            "text": "Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23473590", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 164, 
            "offsetInEndSection": 383, 
            "text": "We evaluated whether intratracheal lucinactant, a synthetic, peptide-containing surfactant, was safe and well-tolerated in infants with acute hypoxemic respiratory failure, and assessed its effects on clinical outcomes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791092", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2555, 
            "offsetInEndSection": 2747, 
            "text": "An improvement in oxygenation and a significantly reduced requirement for retreatment suggests that lucinactant might improve lung function in infants with acute hypoxemic respiratory failure.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22791092", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1316, 
            "offsetInEndSection": 1527, 
            "text": "CONCLUSION: These data suggest that early intervention with lucinactant may more effectively mitigate pulmonary pathophysiological sequelae of RDS than the animal-derived surfactants poractant alfa or beractant.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22821059", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 75, 
            "text": "Lucinactant for the treatment of respiratory distress syndrome in neonates.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032799", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 714, 
            "offsetInEndSection": 977, 
            "text": "The clinical trials that have been performed, although underpowered, may indicate that lucinactant is superior to phospholipid synthetic surfactant preparations and at least as effective as animal-derived surfactants in reducing morbidity and mortality from RDS. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23032799", 
            "endSection": "abstract"
        }
    ]
}